Skip to main content

Dr. Robert A. Mittra, MD

Ophthalmology (Ophthalmology Physician)

  • Medicare participating

At a glance

Years since graduation
30
In the NPI registry since
2005
Medicare patients seen, 2024
968

The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is

Education and training

  • 1996Medical school: Duke University School of Medicine
  • 2005Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier

Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).

Specialties and state licenses

  • Ophthalmology Physician primary
    MN license 42976

As reported to the NPI registry. To confirm a license is current, check the state medical board.

Map: Ophthalmology per capita by county →

Where they work

Medical groups

Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.

Medicare patients and services

Medicare patients, 2024
968
Services billed
25,894
Patients’ average age
78
Most frequent Medicare services, 2023
ServiceTimesPatients
Injection, faricimab-svoa, 0.1 mg5,34019
Injection, ranibizumab-eqrn (cimerli), biosimilar, 0.1 mg3,068176
Imaging of retina2,960982
Injection, aflibercept, 1 mg2,164214
Injection of drug into eye1,900447
Injection, ranibizumab, 0.1 mg1,300119
Established patient complete exam of visual system895637
Established patient problem focused exam of visual system291208
Unclassified biologics27844
Exam of retinal blood vessels using a special camera after injection of a dye207180

Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.

Medicare prescriptions

Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.

Payments from drug and device companies

In 2025, 1 companies reported 2 payments worth $2,940 in total to this clinician.

By company
Genentech USA, Inc.$2,940
By type
Consulting Fee$2,925
Food and Beverage$15.42

What the payments were for

Largest payments other than meals
DateCompanyWhat it was forAmount
Apr 11, 2025Genentech USA, Inc.
Apr 11, 2025
Consulting Fee
Susvimo · Immunology and Ophthalmology
$2,925

Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.

From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.

Who received the most in Minnesota →

Industry-funded research

Named as a principal investigator on 10 industry-funded studies in 2025, from 4 companies. The companies reported $1,127,010 in research payments for these studies, mostly to the institutions running them.

  • A Phase 3b, Single-Arm Study of Aflibercept 8 mg Dosed Every 4 Weeks in Adult Participants With Neovascular Age-Related Macular Degeneration (nAMD) or Diabetic Macular Edema (DME)
    Regeneron Pharmaceuticals, Inc. · Active, not recruiting · NCT06491914
  • Port Delivery System of Ranibizumab Extension Study
    Genentech, Inc.
  • Study of the port delivery system with ranibizumab in patients with diabetic macular edema
    Genentech, Inc.
  • Entry into human of RO7497372 in participants with diabetic macular edema
    Roche Tcrc, Inc.
  • MAD to assess the safety tolerability and PK PD in nAMD patients
    Genentech, Inc.
  • BAY 865321, Randomized, Double-Masked, Active-Controlled, Phase 3 Study of the Efficacy and Safety of Aflibercept 8 mg in Macular Edema Secondary to Retinal Vein Occlusion
    Bayer HealthCare Pharmaceuticals Inc.
  • A Phase IV, Multicenter, Open-label Study to Assess Corneal Endothelial Cells in Patients With Neovascular Age-related Macular Degeneration Treated With the Port Delivery System With Ranibizumab (PDS) (Belvedere)
    Genentech, Inc.
  • BAY 865321, Randomized, Double-Masked, Active-Controlled, Phase 3 Study of the Efficacy and Safety of High Dose Aflibercept in Patients With Neovascular Age-Related Macular Degeneration
    Bayer HealthCare Pharmaceuticals Inc.
  • Ph iii study to evaluate the efficacy and safety of astegolimab in copd
    Genentech, Inc.
  • Port Delivery System for Ranibizumab
    Genentech, Inc.

From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.

Other Ophthalmology clinicians in Minneapolis

Sources

NPI registry (CMS NPPES, November 2026; record last updated November 3, 2010), Medicare Care Compare, Medicare Physician & Other Practitioners (2024), Medicare Part D Prescribers (2024) and Open Payments (2025). Information is self-reported or billed data and may be out of date; call before visiting.

NPI 1699764456. Official NPI registry record (opens in a new tab). Clinicians can correct their information in NPPES; changes appear here after our next monthly update.